Here's What Will Drive AbbVie's Top-line Growth in 2026
unknown
📅 Published: 2026-02-10 13:32
📰 Source: Yahoo
📝 Words: 22
📝 Article Content
ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.
📄 Summary
ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-02-12 12:07:58
Updated At:
2026-02-12 12:07:58
Scraping Job ID:
N/A
Stock Mentions:
ABBV - AbbVie Inc.
Relevance: N/A